Palisade Bio to Participate in the Piper Sandler Virtual Novel Targets in Immunology Symposium

Company Overview - Palisade Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing next-generation, once-daily oral PDE4 inhibitor prodrugs aimed at targeted delivery to the terminal ileum and colon [2][6] - The company's lead program, PALI-2108, is designed to improve pharmacology, tolerability, and convenience for patients with inflammatory and fibrotic diseases [6][7] Product Details - PALI-2108 is a once-daily oral prodrug that is pharmacologically inactive until it reaches the lower intestine, where it is activated by bacterial enzymes at sites of inflammation and fibrosis [5][7] - In a recent Phase 1b trial, PALI-2108 achieved a 100% clinical response in the ulcerative colitis (UC) cohort, with no serious adverse events reported [7] - The company is advancing towards a Phase 2 clinical study in UC, which will evaluate clinical remission, response, and pharmacodynamic biomarkers over 12 weeks [8] Upcoming Events - JD Finley, CEO, and Dr. Mitchell Jones, President and CMO, will participate in a virtual fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026 [2][3] - A live webcast of the presentation will be available on the company's website, with a replay accessible for a limited time [4]